Valuation: Orgenesis Inc.

Market Cap 10L 9L 8L 7L 13.77L 9.46Cr 14.08L 94.73L 37.26L 4.64Cr 36.91L 36.1L 16Cr P/E 2023
-0.26x
P/E 2024 -0.17x
Enterprise Value 1.92Cr 1.67Cr 1.55Cr 1.42Cr 2.68Cr 184.55Cr 2.74Cr 18Cr 7.27Cr 90Cr 7.2Cr 7.04Cr 311.15Cr EV / Sales 2023
71.2x
EV / Sales 2024 27x
Free-Float
52.06%
Yield 2023 *
-
Yield 2024 -
1 day+320.00%
1 week-98.87%
Current month-98.95%
1 month-98.68%
3 months-97.38%
6 months-97.29%
Current year-97.20%
1 week 0
Extreme 0.001
0.45
1 month 0
Extreme 0.001
0.52
Current year 0
Extreme 0.001
0.84
1 year 0
Extreme 0.0001
1.08
3 years 0
Extreme 0.0001
12.9
5 years 0
Extreme 0.0001
54.9
10 years 0
Extreme 0.0001
168
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 72 02/02/2012
Chief Executive Officer 57 24/12/2013
Director of Finance/CFO 51 10/03/2026
Director TitleAgeSince
Chairman 57 14/08/2014
Director/Board Member 55 17/04/2012
Director/Board Member 64 08/07/2024
Date Insider Type Main position Quantity % Market Cap.
05/03/25 Other 12,00,000 23.2142%
12/12/24 Free

Director

1,875 0.0363%
12/12/24 Free

Director

1,750 0.0339%
Change 5-day change 1-year change 3-year change Capi.($)
+320.00%-98.87%-99.62%-99.97% 41.16T
+1.87%+7.19%-16.46%-5.91% 18TCr
-0.43%-0.80%-7.07%-4.05% 11TCr
-0.03%+1.47%+4.59%+60.25% 5.99TCr
+0.66%+0.96%+37.56%+53.38% 5.2TCr
-1.10%+4.10%-12.56%-38.37% 4.36TCr
-3.21%-3.05% - - 3.36TCr
-1.71%+2.25%-8.86%-44.23% 2.96TCr
-1.16%+1.28%+61.67%-6.62% 2.53TCr
-1.49%+0.85%-3.01%-4.60% 2.12TCr
Average +31.34%-8.46%-4.86%-10.01% 5.47TCr
Weighted average by Cap. +0.09%+2.75%-1.41%+3.25%

Financials

2023 2024
Net sales 5L 5L 4L 4L 7L 5.1Cr 8L 51.08L 20.09L 2.5Cr 19.9L 19.47L 8.61Cr 10.35L 9L 8L 8L 14.5L 9.97Cr 14.82L 99.76L 39.24L 4.88Cr 38.87L 38.02L 17Cr
Net income -5.54Cr -4.84Cr -4.46Cr -4.12Cr -7.76Cr -533.13Cr -7.93Cr -53Cr -21Cr -261.11Cr -21Cr -20Cr -898.86Cr -4.82Cr -4.21Cr -3.88Cr -3.58Cr -6.75Cr -463.84Cr -6.9Cr -46Cr -18Cr -227.17Cr -18Cr -18Cr -782.02Cr
Net Debt 2.18Cr 1.9Cr 1.76Cr 1.62Cr 3.05Cr 209.78Cr 3.12Cr 21Cr 8.26Cr 102.74Cr 8.18Cr 8Cr 353.69Cr 1.82Cr 1.59Cr 1.47Cr 1.35Cr 2.55Cr 175.09Cr 2.6Cr 18Cr 6.89Cr 86Cr 6.83Cr 6.68Cr 295.19Cr
Logo Orgenesis Inc.
Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). The Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.
Employees
77
Date Price Change Volume
17/26/17 $0.004200 +320.00% 1,010
16/26/16 $0.001000 -94.74% 100
15/26/15 $0.0190 -5.00% 112
14/26/14 $0.0200 +1,900.00% 369
13/26/13 $0.001000 -99.73% 1,232
  1. Stock Market
  2. Stocks
  3. ORGS Stock